Back to News
Feb 11, 2026 12:02 PM

Gilead Climbs Nearly 5% Following Strong Quarter, Bullish Analyst Calls

Shares of Gilead Sciences Inc (NASDAQ:GILD) rallied in early trading on Wednesday after the company reported upbeat fourth-quarter results.

Here are the key analyst insights:

Cantor Fitzgerald analyst Carter Gould reiterated an Overweight rating, while raising the price target from $135 to $155.

Scotiabank analyst Louise Chen maintained a Sector Outperform rating and raised the price target from $140 to $177.

Needham analyst Joseph Stringer reiterated a Buy rating, while listing the price target from $140 to $170.

Check out other analyst stock ratings.

Cantor Fitzgerald: Gilead Sciences reported both revenue and non-GAAP earnings ahead of expectations. The beats were driven by continued strength in the HIV and liver disease businesses, oncology and cell therapy remained headwinds.

The 2026 guidance for Yeztugo of $800 million came in below the $844 million consensus, Gould said in a note. "However, we view the ...